Brentuximab Vedotin Plus Bendamustine Safe, Effective as Second-line Hodgkin Lymphoma Treatment
Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.
Hodgkin Lymphoma
Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine Prolongs PFS in Hodgkin Lymphoma
Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.
Brentuximab Vedotin Plus Nivolumab May Be Effective Salvage Therapy for Hodgkin Lymphoma
Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.
Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma
An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.
Hodgkin Lymphoma: Assay May Predict Post-transplantation Relapse, Possibly Guiding Non-transplant Options
The gene expression-based prognostic model, RHL30, has the potential to provide insights for the selection of treatment strategies catered to the individual patient.
Hodgkin Lymphoma: Risk-adapted Therapy Recommended
Long-term follow-up data from randomized trials on Hodgkin lymphoma support current risk-adapted therapeutic approaches for early-stage disease.
Pembrolizumab Effective Regardless of Prior Therapy in Classical Hodgkin Lymphoma
Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.
Hodgkin Lymphoma Survivors at Risk for Second Cancers
Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.
Hodgkin Lymphoma: Nivolumab Active After Allogeneic HCT
PD-1 blockade with nivolumab was active in patients with Hodgkin lymphoma who received allogeneic hematopoietic cell transplantation.
Hodgkin Lymphoma: Intensifying Treatment With Rituximab After PET
Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.
Next post in Lymphoma
